Utama › Leukemia Mieloid Akut › New Jersey › Newark
Kajian klinikal Leukemia Mieloid Akut di Newark, NJ
12 kajian untuk Leukemia Mieloid Akut sedang mencari peserta di lokasi dalam dan sekitar Newark (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.
Teks kajian rasmi (Bahasa Inggeris)
Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
- Morristown Medical Center, Morristown · 17 mi jauh
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
Mengambil pesertaFasa 2
- Cooperman Barnabas Medical Center, Livingston · 9 mi jauh
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Mengambil pesertaFasa 2
- Cooperman Barnabas Medical Center, Livingston · 9 mi jauh
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
Mengambil pesertaFasa 2
- Cooperman Barnabas Medical Center, Livingston · 9 mi jauh
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
Mengambil pesertaFasa 2
- Cooperman Barnabas Medical Center, Livingston · 9 mi jauh
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
Mengambil pesertaFasa 2
- Cooperman Barnabas Medical Center, Livingston · 9 mi jauh
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
Mengambil pesertaFasa 3
- Newark Beth Israel Medical Center, Newark
- Morristown Medical Center, Morristown · 17 mi jauh
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Mengambil pesertaFasa 1/2
- Atlantic Health, Morristown · 17 mi jauh
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
Mengambil pesertaFasa 1/2
- Morristown Medical Center, Morristown · 17 mi jauh
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
Mengambil pesertaFasa 3
- Morristown Medical Center, Morristown · 17 mi jauh
L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML
Mengambil pesertaFasa 2/3
- Atlantic Health, Morristown · 17 mi jauh
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Mengambil pesertaFasa 1/2
- Atlantic Health, Morristown · 17 mi jauh
Kajian Leukemia Mieloid Akut di bandar lain
- Houston, TX85 kajian
- New York City, NY51 kajian
- Boston, MA44 kajian
- Baldwin Park, CA40 kajian
- Seattle, WA40 kajian
- Columbus, OH35 kajian
- Philadelphia, PA34 kajian
- Durham, NC33 kajian
- Atlanta, GA30 kajian
- Tampa, FL29 kajian
- Chicago, IL26 kajian
- Portland, OR25 kajian
Kajian lain di Newark
- Kanser Payudara18 kajian
- Kanser Paru-paru Bukan Sel Kecil14 kajian
- Kecederaan Sumsum Tulang Belakang13 kajian
- Kanser Metastatik10 kajian
- Kegagalan Jantung10 kajian
- Kanser Pankreas9 kajian
- Penyakit Kardiovaskular9 kajian
- Melanoma8 kajian
- Kanser Paru-paru7 kajian
- Kanser (semua jenis)7 kajian
- Penyakit Crohn7 kajian
- Strok6 kajian
Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.